Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 20 versus ENOVID E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 20 versus ENOVID E.
AUROVELA 1/20 vs ENOVID-E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Combination estrogen-progestin contraceptive. Suppresses gonadotropin release, inhibits ovulation, increases cervical mucus viscosity, and alters endometrial morphology.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
5 mg orally once daily for 20 days starting on day 5 of menstrual cycle
None Documented
None Documented
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
Norethynodrel: 5-10 hours; mestranol: 2-5 hours (metabolized to ethinyl estradiol, half-life 10-20 hours). Steady-state reached in 5-7 days.
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Renal (50-60% as metabolites, <1% unchanged); fecal (40-50%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive